MannKind Corp. (MNKD)
4.06
+0.10
(+2.53%)
USD |
NASDAQ |
Sep 04, 16:00
4.03
-0.03
(-0.74%)
After-Hours: 20:00
MannKind Research and Development Expense (Quarterly) : 18.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.00M |
| March 31, 2026 | 17.23M |
| December 31, 2025 | 27.59M |
| September 30, 2025 | 14.06M |
| June 30, 2025 | 13.68M |
| March 31, 2025 | 11.02M |
| December 31, 2024 | 11.14M |
| September 30, 2024 | 12.93M |
| June 30, 2024 | 11.82M |
| March 31, 2024 | 10.01M |
| December 31, 2023 | 9.236M |
| September 30, 2023 | 9.989M |
| June 30, 2023 | 6.453M |
| March 31, 2023 | 5.605M |
| December 31, 2022 | 7.156M |
| September 30, 2022 | 4.136M |
| June 30, 2022 | 4.893M |
| March 31, 2022 | 3.536M |
| December 31, 2021 | 3.886M |
| September 30, 2021 | 3.655M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 2.442M |
| December 31, 2020 | 1.545M |
| September 30, 2020 | 1.484M |
| June 30, 2020 | 1.464M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.755M |
| December 31, 2019 | 2.021M |
| September 30, 2019 | 1.58M |
| June 30, 2019 | 1.632M |
| March 31, 2019 | 1.667M |
| December 31, 2018 | 1.083M |
| September 30, 2018 | 2.043M |
| June 30, 2018 | 2.967M |
| March 31, 2018 | 2.644M |
| December 31, 2017 | 3.507M |
| September 30, 2017 | 4.361M |
| June 30, 2017 | 3.123M |
| March 31, 2017 | 3.129M |
| December 31, 2016 | 1.559M |
| September 30, 2016 | 3.217M |
| June 30, 2016 | 4.357M |
| March 31, 2016 | 5.22M |
| December 31, 2015 | 6.218M |
| September 30, 2015 | 4.898M |
| June 30, 2015 | 7.825M |
| March 31, 2015 | 9.465M |
| December 31, 2014 | 17.56M |
| September 30, 2014 | 19.78M |
| June 30, 2014 | 37.41M |
| March 31, 2014 | 26.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp. | 146.30M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Gilead Sciences, Inc. | 1.69B |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Ocugen, Inc. | 10.69M |